Category
    Regions
    Category
    Regions
    Reset Showing 1 – 10 of 37
    VIRBAC SWOT, Financial and Strategic Analysis Report 2025

    Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of VIRBAC. VIRBAC business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of VIRBAC are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of VIRBAC , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of VIRBAC including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of VIRBAC and all latest updates of the company are provided. The 2025 version of VIRBAC report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Nov-2025

    $50
    $50
    $50
    Sanofi ADS SWOT, Financial and Strategic Analysis Report 2025

    Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Sanofi ADS. Sanofi ADS business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Sanofi ADS are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Sanofi ADS , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Sanofi ADS including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Sanofi ADS and all latest updates of the company are provided. The 2025 version of Sanofi ADS report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Aug-2025

    $50
    $50
    $50
    SANOFI SWOT, Financial and Strategic Analysis Report 2025

    Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of SANOFI. SANOFI business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of SANOFI are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of SANOFI , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of SANOFI including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of SANOFI and all latest updates of the company are provided. The 2025 version of SANOFI report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Aug-2025

    $50
    $50
    $50
    Roche Holding AG SWOT, Financial and Strategic Analysis Report 2025

    Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Roche Holding AG. Roche Holding AG business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Roche Holding AG are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Roche Holding AG , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Roche Holding AG including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Roche Holding AG and all latest updates of the company are provided. The 2025 version of Roche Holding AG report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Aug-2025

    $50
    $50
    $50
    Rite Aid Corporation SWOT, Financial and Strategic Analysis Report 2025

    Rite Aid Corporation, through its subsidiaries, operates a chain of retail drugstores in the United States. The company operates through two segments, Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment sells prescription drugs and provides various other pharmacy services and an assortment of products comprising over-the-counter medications, health and beauty aids, personal care products, seasonal merchandise, cosmetics, household items, food and beverages, greeting cards, seasonal and general merchandise, pet care, and a variety of other everyday and convenience products, as well as brand and generic prescription drugs; and a private brand product line. It also operates retail pharmacies and clinics; and offers healthcare services, including administering immunizations for COVID-19, the flu, shingles, and others; assists its customers with high blood pressure, cholesterol, and diabetes; provides guidance on combating obesity and tobacco addiction; and educates customers on managing medications and potential side effects. In addition, this segment offers healthcare coaching and disease management services to health plans and employers. The Pharmacy Services segment provides integrated suite of pharmacy benefit management (PBM) offerings, including technology solutions, mail delivery services, specialty pharmacy, network and rebate administration, claims adjudication, and pharmacy discount programs, as well as drug benefits under the federal government's Medicare Part D program and insurance offerings for individuals and groups. This segment serves health plans, commercial employers, labor groups, and state and local governments. As of February 26, 2022, the company operated 2,450 retail pharmacy locations in 17 states. Rite Aid Corporation was founded in 1962 and is headquartered in Philadelphia, Pennsylvania. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Rite Aid Corporation. Rite Aid Corporation business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Rite Aid Corporation are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Rite Aid Corporation , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Rite Aid Corporation including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Rite Aid Corporation and all latest updates of the company are provided. The 2025 version of Rite Aid Corporation report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Sep-2025

    $100
    $100
    $100
    AbbVie Inc. SWOT, Financial and Strategic Analysis Report 2025

    AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of AbbVie Inc.. AbbVie Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of AbbVie Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of AbbVie Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of AbbVie Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of AbbVie Inc. and all latest updates of the company are provided. The 2025 version of AbbVie Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Sep-2025

    $100
    $100
    $100
    Walgreens Boots Alliance Inc. SWOT, Financial and Strategic Analysis Report 2025

    Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and beauty retail company. It operates through two segments, the United States and International. The United States segment sells prescription drugs and an assortment of retail products, including health, wellness, beauty, personal care, consumable, and general merchandise products through its retail drugstores. It also provides central specialty pharmacy services and mail services. As of August 31, 2021, this segment operated 8,965 retail stores under the Walgreens and Duane Reade brands in the United States; and five specialty pharmacies. The International segment sells prescription drugs; and health and wellness, beauty, personal care, and other consumer products through its pharmacy-led health and beauty retail stores and optical practices, as well as through boots.com and an integrated mobile application. It also engages in pharmaceutical wholesaling and distribution business in Germany. As of August 31, 2021, this segment operated 4,031 retail stores under the Boots, Benavides, and Ahumada in the United Kingdom, Thailand, Norway, the Republic of Ireland, the Netherlands, Mexico, and Chile; and 548 optical practices, including 160 on a franchise basis. Walgreens Boots Alliance, Inc. was founded in 1901 and is based in Deerfield, Illinois. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Walgreens Boots Alliance Inc.. Walgreens Boots Alliance Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Walgreens Boots Alliance Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Walgreens Boots Alliance Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Walgreens Boots Alliance Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Walgreens Boots Alliance Inc. and all latest updates of the company are provided. The 2025 version of Walgreens Boots Alliance Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Sep-2025

    $100
    $100
    $100
    Recordati S.p.A. SWOT, Financial and Strategic Analysis Report 2025

    Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, marketing, and sale of pharmaceuticals worldwide. The company offers pharmaceuticals in various therapeutic areas, including cardiovascular, dermatology, over the counter/non-prescription pharmaceuticals, urology, anti-infectives, central nervous system, gastrointestinal, gynecology and obstetrics, musculo-skeletal disorders and analgesia, nutrition and related products, cosmetics, dietary supplements, medical devices, allergy, endocrinology, respiratory, pain management/inflammation, generics, antipyretics and cold preparations, and oncology, as well as ear, nose, and throat. It also provides products for rare diseases; and pharmaceutical chemicals, such as chemical syntheses, active pharmaceutical ingredients, and intermediates. The company was founded in 1926 and is headquartered in Milan, Italy. Recordati Industria Chimica e Farmaceutica S.p.A. operates as a subsidiary of Rossini S.à R.L. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Recordati S.p.A.. Recordati S.p.A. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Recordati S.p.A. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Recordati S.p.A. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Recordati S.p.A. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Recordati S.p.A. and all latest updates of the company are provided. The 2025 version of Recordati S.p.A. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    $50
    $50
    Pfizer Inc. SWOT, Financial and Strategic Analysis Report 2025

    Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Pfizer Inc.. Pfizer Inc. business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Pfizer Inc. are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Pfizer Inc. , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Pfizer Inc. including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Pfizer Inc. and all latest updates of the company are provided. The 2025 version of Pfizer Inc. report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    $50
    $50
    Orion Oyj B SWOT, Financial and Strategic Analysis Report 2025

    Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland. The 2025 version of the report offers detailed insights into the company's strategies, developments, outlook and drivers. In addition to SWOT Analysis and Financial Overview, the report analyzes key projects, business description, products, services, brands, operating locations, subsidiaries and affiliates of Orion Oyj B. Orion Oyj B business operations across the value chain are included. Further, all major operating and planned locations, related contacts, details of subsidiaries and partnerships of Orion Oyj B are also analyzed. Detailed SWOT Analysis of the company including key strengths and weaknesses of Orion Oyj B , on which it can build its business along with potential opportunities and threats in the near to medium term future are detailed. Key employees of the company including the management team and board of directors are listed with their designations. Further, statistics on key parameters such as employee count, organization structure etc is provided. Financial analysis of Orion Oyj B including key ratios, income statement, cash flow statement and balance sheet are provided for the company. In addition, Key historical events, summary analysis of Orion Oyj B and all latest updates of the company are provided. The 2025 version of Orion Oyj B report is presented after intensive primary and secondary research processes and it presents the insights in a complete impartial and reader friendly format.

    Published: Jan-1970

    $50
    $50
    $50